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Physiologically based pharmacokinetic (PBPK) models integrate both chemical- and
system-specific information into a mathematical framework, offering a mechanistic
approach to predict the internal dose metrics of a chemical and an ability to perform
species and dose extrapolations. Bisphenol A (BPA), because of its ubiquitous presence
in a variety of consumer products, has received a considerable amount of attention from
the public and regulatory bodies. PBPK models using deuterated BPA were developed for
immature and adult rats and non-human primates and for adult humans to understand
better the dosimetry of BPA. The focus of the present paper is to provide a rationale
for interpreting species- and age-related pharmacokinetics of BPA. Gastrointestinal tract
metabolism was an important consideration to predict unconjugated BPA serum kinetic
profiles in adult and immature rats and monkeys. Biliary excretion and enterohepatic
recirculation of BPA conjugates (BPA-c) accounted for the slowed systemic clearance of
BPA-c in rats. For monkeys, renal reabsorption was proposed as a mechanism influencing
systemic clearance of BPA-c. The quantitative understanding of the processes driving the
pharmacokinetics of BPA across different species and life stages using a computational
modeling approach provides more confidence in the interpretation of human biomonitoring
data and the extrapolation of experimental animal findings to humans.
Keywords: bisphenol A, PBPK, pharmacokinetics, age-dependent pharmacokinetics, species extrapolation,
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INTRODUCTION
Physiologically based pharmacokinetic (PBPK) modeling, with its
integration of physiological and biochemical processes, provides
a quantitative description of the pharmacokinetics of the parent
chemical and its metabolite(s). Compared with empirical com-
partmental models that lack physiological and biochemical fea-
tures, PBPK models allow for extrapolation of the kinetic behav-
ior of chemicals across routes of exposure, doses and species.
PBPK models help reduce the uncertainty associated with extrap-
olation of toxicity findings in laboratory animals to humans.
Bisphenol A (BPA), a high production volume industrial
chemical, has been widely used for the manufacture of poly-
carbonate plastics and epoxy resins, both of which have broad
applications in consumer products, medical devices, and the
printing industry (Willhite et al., 2008). Over 90% of people in the
US have detectable levels of BPA in their urine (Calafat et al., 2008;
Koch et al., 2012). Several in vitro and in vivo toxicity assessments
have been reported (Richter et al., 2007; NTP, 2008; WHO, 2011;
Vandenberg et al., 2012).
To understand better the kinetics of BPA in laboratory animals
and humans, a series of kinetic studies were conducted at the
Abbreviations: BPA, bisphenol A; BPA-c, bisphenol A conjugates; BPA-glu,
bisphenol A glucuronide; d6-BPA, deuterated bisphenol A; GI, gastrointesti-
nal; i.v., intravenous; PBPK, physiologically based pharmacokinetic modeling;
PND, postnatal day; UGT, UDP-glucuronosyltransferase.
U.S. Food and Drug Administration’s National Center for Toxi-
cological Research (NCTR) in rats, mice, and monkeys, including
various life stages (Doerge et al., 2010a,b, 2011a). Single dose
pharmacokinetic studies were undertaken using a relatively low
dose (100 µg/kg) of deuterated BPA (d6-BPA). The use of d6-BPA
provided a contaminant-free method to measure BPA in biologi-
cal tissues and using a low dose of d6-BPA provided kinetic time
course behaviors that would be expected to be relevant to typical
aggregate environmental exposures of <1 µg/kg/day in humans
(USFDA, 2010; Lakind and Naiman, 2011; USCDC, 2014). This
manuscript explains our thinking for how we unraveled some of
the route- and age-specific complexities of BPA kinetics described
in the papers of Fisher et al. (2011) and Yang et al. (2013). This is
important because other recent important PBPK models for BPA
(Teeguarden et al., 2005; Edginton and Ritter, 2009; Mielke and
Gundert-Remy, 2009) were carefully reviewed by EFSA (2014)
and do not include presystemic metabolism in the gastrointestinal
(GI) tract, a feature in our BPA models that helped to predict the
extremely low oral systemic bioavailability of BPA. In addition,
our rationale is explained for species extrapolation (scaling) of
BPA model parameters in non-human primates to humans.
INTRAVENOUS DOSING WITH d6-BPA
Armed with several high quality kinetic studies with d6-BPA
in rats and monkeys (Doerge et al., 2010a,b), the initial PBPK
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model development focused on adult monkeys and rats dosed
intravenously (i.v.) with d6-BPA. This was the least problematic
route of administration and demonstrated classic flow-limited
kinetic behavior for hepatic metabolism. The dose of d6-BPA was
small; thus hepatic extraction (BPA conjugation) greatly exceeded
the rate at which the blood supply perfused the liver with BPA.
We knew that the rate of BPA conjugation was very fast because
of the rapid disappearance of the parent BPA from serum and
the prompt appearance of metabolites in serum (Doerge et al.,
2010a,b). This occurred in every species tested at NCTR (mice,
rats, and monkeys). The unconjugated d6-BPA kinetic behavior
appeared uncomplicated (generally log-linear) after i.v. adminis-
tration (Doerge et al., 2010a,b); however the d6-BPA conjugate
behavior seemed more complex because of its prolonged terminal
clearance phase.
A mass conservation equation, which implies that a com-
partment is well-stirred (uniform), was used to represent each
model compartment. The solubility of BPA in the compart-
ment (tissue/serum or blood partition coefficient), the concen-
tration of BPA in blood or serum, and the perfusion rate of the
compartment described the rate of BPA uptake and clearance
from the compartment. An additional equation accounted for
the metabolism of BPA in the liver. In our models, one of the
simplifying assumptions was that the rate of formation of the
metabolites was set equal to the rate of metabolism of d6-BPA.
Hepatic BPA conjugation in rats was estimated using in vitro to in
vivo extrapolation (IVIVE). A Michaelis–Menten equation, where
the Michaelis constant was set equal to the reported in vitro Km
value determined with native hepatic microsomes from adult rats
(Mazur et al., 2010), and the maximum hepatic reaction velocity
was derived by scaling of the in vitro maximal velocity to predict
rat serum time course data for d6-BPA (Doerge et al., 2010a). For
monkeys, hepatic conjugation of BPA was determined by fitting
serum d6-BPA time course data from i.v. dosing, using a first
order metabolic constant (Doerge et al., 2010b).
The general success of the PBPK model to predict d6-BPA
kinetics after i.v. administration in the rat and monkey (Figure 2
in Yang et al., 2013 and Figures 2 and 3 in Fisher et al., 2011)
suggested that BPA kinetic behaviors in rats and monkeys were
similar to many other well-metabolized chemicals that have been
previously described using venous equilibration equations (Reddy
et al., 2005). The notion that BPA is sequestered and retained
in some part of the body, such as fat (Stahlhut et al., 2009), is
highly improbable. The solubility of d6-BPA in fat relative to
serum in rats was 5.0 at 2 h after i.v. dosing (Doerge et al., 2011b).
Using vial equilibration and human tissues a fat:blood partition
coefficient value of 3.3 was determined (Csanady et al., 2002).
Similar to experimental findings, using structure-activity algo-
rithms (Rodgers et al., 2005; Rodgers and Rowland, 2006; Schmitt,
2008), fat:blood and fat:plasma partition coefficients of BPA in
humans were calculated to be 3.3 (Mielke et al., 2011; Partosch
et al., 2013) and 8.3 (Edginton and Ritter, 2009). In addition, in
adult mice the clearance of d6-BPA from fat paralleled the serum
clearance of d6-BPA after i.v. dosing, signifying rapid equilibrium
between blood and fat stores (Doerge et al., 2012). If d6-BPA
were a highly fat soluble chemical, the expected behavior of d6-
BPA in fat of adult rats would be much different (Figure 1) than
what was observed 2 h after dosing (Doerge et al., 2011b). BPA is
a moderately lipophilic chemical (log kow ∼ 3; Borrirukwisitsak
et al., 2012) that equilibrates with tissues (diffuses into and out of
tissues) freely.
For monkeys and rats, experimental studies demonstrated that
the primary conjugate was the BPA glucuronide (BPA-glu), with
the sulfate accounting for <20% for monkeys and <5% for rats
(Doerge et al., 2010b). In monkeys, radioactive BPA administered
by i.v. injection was excreted principally in urine (74–82%), with
<3% found in feces (Kurebayashi et al., 2002). In rats, only 6–8%
of the i.v. administered radioactive BPA was recovered in urine,
with a much larger fraction excreted in feces as unconjugated
BPA (46–49%; Kurebayashi et al., 2003). These conjugates are
not associated with receptor-mediated toxicity of BPA. A simple
modeling approach using one (monkey) or three (rat) compart-
ments was sufficient to represent the conjugates as total BPA con-
jugates (BPA-c). Two different approaches were used to describe
the systemic clearance of BPA-c. For rats, biliary excretion and
enterohepatic recirculation of BPA-c were included in the model
because BPA-glu was identified as a potential substrate of rat
MRP2 (Mazur et al., 2012), which is an efflux pump present at the
canalicular pole of rat hepatocytes (Ito et al., 1997). Eighty seven
percent of BPA-glu formed in the liver was found to be excreted
into the bile of rats (Inoue et al., 2005). Sakamoto et al. (2002)
reported the de-conjugation of BPA-glu in the terminal region of
the small intestine by bacteria, and the reabsorption of the formed
unconjugated BPA. To describe the excretion of BPA-c into the
bile, a Michaelis–Menten equation was used, based on experimen-
tal findings with monoglucuronosyl bilirubin and MRP2 (Jemnitz
et al., 2010) and BPA biliary excretion data reported by Inoue et al.
(2005). The mathematical description of enterohepatic recircula-
tion (biliary excretion, bacterial deconjugation, reabsorption, and
fecal excretion) simply used non-physiological terms constrained
to predict slowed systemic clearance of serum BPA and BPA-c
(Doerge et al., 2010a), and the reported fecal excretion of BPA
(Kurebayashi et al., 2003). Unraveling some of the complexities
of the GI tract for i.v. administration of 100 µg/kg of d6-BPA
resulted in model predictions (and assumptions) that BPA-c
formed in the liver was predominantly excreted into the bile, with
only a very small portion (less than 1%) entering the systemic
circulation. The biliary excreted BPA-c was subject to deconjuga-
tion in the terminal region of the GI tract. The majority (90%)
of the unconjugated BPA formed in the gut lumen by bacteria
was predicted to enter the enterocyte, undergo conjugation, and
move into systemic circulation as BPA-c. The reminder of the
unconjugated BPA was reabsorbed from the enterocyte into the
system or excreted into feces.
In non-human primates (Kurebayashi et al., 2002) and
humans (Völkel et al., 2002), BPA is predominantly excreted in
the urine as BPA-c, thus BPA-c was not expected to be excreted in
bile. Therefore, only a minimal effort was undertaken to evaluate
the role of biliary excretion of d6-BPA-c in monkeys. Nevertheless,
in order to predict the slowed systemic clearance of d6-BPA-c
in monkeys, it was necessary to assume that a small fraction
of d6-BPA-c underwent renal reabsorption (Fisher et al., 2011).
This process was described with a Michaelis–Menten equation,
based on the reported affinity of HEK-MRP2 toward bilirubin
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FIGURE 1 | Model simulated time course of d6-BPA concentrations (solid lines) in the fat of adult rats following i.v. dosing of 100 µg/kg d6-BPA with
different fat to blood partition coefficients (PC) assumed, and measured d6-BPA concentration (•) in the fat at 2 h after dosing (Doerge et al., 2011b).
bisglucuronosyl (Jemnitz et al., 2010) and a maximum velocity
term fitted to serum d6-BPA-c concentrations.
For humans, renal reabsorption may also play a role in the
kinetic behavior of BPA-c. BPA-glu was identified as a potential
human MRP3 substrate (Mazur et al., 2012). Weak expression of
MRP3 has been observed in human kidney cell lines (Hilgendorf
et al., 2007) and tissues located on the basolateral membranes
(Scheffer et al., 2002). Renal reabsorption of BPA-c was later
removed for human simulations (Fisher et al., 2011) because
of the lack of direct support for recycling of BPA-c in the
kidney.
ORAL DOSING WITH d6-BPA
Because oral ingestion of BPA through the diet is the primary
route of human exposure to BPA, NCTR conducted oral bolus
gavage pharmacokinetic studies with d6-BPA in rats and monkeys
using an aqueous vehicle (Doerge et al., 2010a,b). In Germany,
oral dosing pharmacokinetic studies in humans were carried out
with d16-BPA in a hard gelatin capsule (Völkel et al., 2002).
These studies were used for the calibration of the orally dosed
BPA in monkeys, rats, and humans, where the calibrated mon-
key model was extended to humans with the incorporation of
human-specific physiological model parameters (Fisher et al.,
2011). After oral bolus gavage of monkeys and rats with d6-BPA,
unconjugated BPA only accounted for a very small fraction of
the total dose based on non-compartmental analysis estimates.
This was also true for humans ingesting d16-BPA, where only
conjugated BPA was detectable in plasma. With such a low oral
systemic bioavailability, our first exploratory evaluation using
a PBPK model (calibrated for i.v. administration of d6-BPA)
was to determine the influence of gastric emptying time and
the rate of uptake of d6-BPA into the system from the gut
lumen. Despite several combinatorial attempts to fit the data by
adjusting the values for gastric emptying and the oral uptake
rate of d6-BPA in the monkey and the rat, the model failed
to predict the low serum concentrations of unconjugated BPA
and its conjugated metabolites. We then speculated that a non-
hepatic metabolic loss of d6-BPA was occurring based on the
similar serum profiles of d6-BPA metabolites for both routes of
administration.
From the literature, we found that the GI tract plays a major
role in the metabolism of BPA. Inoue et al. (2003) reported BPA
glucuronidation during its movement through the intestinal wall
using a rat everted small intestine preparation. In other studies
with rat intestinal microsomes, the rates of BPA glucuronida-
tion were characterized (Ito et al., 2005; Mazur et al., 2010).
Which UDP-glucuronosyltransferase (UGT) enzyme isoforms
are responsible for BPA glucuronidation within rat intestine is
unknown. Although there was no direct evidence for monkeys,
GI tract BPA glucuronidation has been documented in human
intestinal preparations (Mazur et al., 2010) and the human
colon adenocarcinoma cell line (Audebert et al., 2011). Thus,
we introduced a metabolism term for BPA in the GI tract for
both rats and monkeys. For small experimental doses of BPA
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(100 µg/kg), presystemic metabolism of BPA within enterocytes
was vital to obtain agreement between model predictions and
observed serum time course profiles for d6-BPA in monkeys and
rats after oral administration of d6-BPA. For rats, a composite
first order term, representing the metabolism of BPA in the gut
and the active transport of d6-BPA-c into the portal blood supply
(see below), was derived by scaling an in vitro metabolic clearance
rate (Ito et al., 2005) to describe the time course of serum d6-BPA
and d6-BPA-c levels. For monkeys, gut metabolism of BPA was
described using a first order metabolic term determined by visual
fitting to serum d6-BPA concentration profiles after oral dosing
(Doerge et al., 2010b). In humans, the scaled first order metabolic
term derived from monkeys was used because of the lack of serum
time course data for unconjugated BPA.
The unraveling of BPA kinetic behavior continued after
GI tract metabolism of BPA was introduced into the model.
To accommodate the rapid appearance of peak systemic levels
of BPA-c, the fraction of BPA-c formed in enterocytes must be
actively transported into systemic circulation. BPA-glu was iden-
tified as a potential substrate for the protein transporter MRP3
(Mazur et al., 2012). The presence of MRP3 on the basolateral
membrane of enterocytes (Inokuchi et al., 2001; Rost et al.,
2002) was hypothesized to account for the rapid active transport
of BPA-c from enterocytes into the portal blood supply. Some
evidence was available to support this assumption. Transport
of BPA-glu from enterocytes into the serosal (blood) side was
observed in the everted small intestine preparation of rats (Inoue
et al., 2003). The influx of d6-BPA-c into the systemic circulation
from enterocytes of monkeys and humans was described with a
visually fitted first order term to predict serum levels of d6-BPA-c
in monkeys after i.v. dosing. For rats, BPA-c produced from
conjugation of BPA in enterocytes was assumed to be secreted
instantaneously into the portal blood supply and this immediate
transport process, along with the gut metabolism of BPA, was
described with a composite first order constant.
d6-BPA DOSING OF INFANTS
The concern about BPA exposure to sensitive sub-populations,
such as infants and children, remains a research topic of interest.
Thus, pharmacokinetic studies with d6-BPA were conducted in
young monkeys and rats at NCTR (Doerge et al., 2010a,b). One
very interesting contrast between immature rats and monkeys was
that in rats, systemic d6-BPA exposure increased with decreasing
age, but in monkeys, there was little difference in systemic d6-
BPA exposure across all ages, [i.e., from postnatal day (PND) 5
to adults]. The adult PBPK models for oral administration of
d6-BPA were modified to account for age-specific physiological
model parameters and where literature information allowed, age-
specific information for BPA was used. For example, Matsumoto
et al. (2002) reported on the maturation of expression and activity
toward BPA for UGT2B1, which is the predominant enzyme
responsible for BPA glucuronidation in rat liver. Therefore, the
metabolic constants representing the hepatic metabolism of BPA
for young rats were initially set to a fraction of adult values to
account for the reported maturity of hepatic UGT activity toward
BPA and further adjusted to achieve agreement with serum d6-
BPA and d6-BPA-c concentrations. In addition, Tomer et al.
(2003) reported age-dependent changes for mRNA and protein
levels of MRP2 in rat pup livers. As such, biliary excretion of
BPA-c for pups was assumed to increase with age in accordance
with the reported protein MRP2 levels.
Nevertheless, for the immature rat and monkey, the serum
time-course kinetics provided the most important information.
A fit-for-purpose approach was used where model predictions
were accomplished by adjusting model parameters to obtain
a consistent agreement between predictions and observations.
Exploration of model parameters across different life stages sug-
gested that the monkey and the rat display different patterns of
maturation with respect to the metabolism of BPA. Immature
monkeys and rats were predicted to have different maturation tra-
jectories for hepatic metabolism of d6-BPA. The hepatic capacity
to metabolize d6-BPA in young monkeys was predicted to be 8-
to 15-fold less than the adult monkey, while for immature rats,
in particular for PND10 and younger rats, the fold difference
compared to adult rats was up to 282-fold. GI tract metabolism
in the immature monkey was assumed to be much more active
than in the immature rat, such that when combined with hepatic
maturation, resulted in profound species differences (Figure 2) in
pharmacokinetic profiles. Figure 2 shows model predicted peak
concentration (Cmax) and the area under the serum concentration
curve (AUC) of unconjugated BPA at steady state in rats, mon-
keys, and humans following repeated daily oral dosing of 50µg/kg
of BPA. As shown in Figure 2, the dose metrics of d6-BPA for
PND10 and younger rats are greater than that in older rats, adult
or infant monkeys, or adult humans.
Our speculation is that the infant monkey pharmacokinetic
d6-BPA behavior is more representative of infants than using the
immature rat pharmacokinetic d6-BPA behavior. The extrapola-
tion of the newborn monkey model (PND5) to newborn humans
resulted in steady-state average plasma BPA concentration of
0.002 µg/L for newborn humans after oral dosing of 1 µg/kg/day
of BPA, which is 23 times less compared to the prediction of
Edginton and Ritter (2009; 0.046 µg/L). As discussed above,
for our modeling efforts, maturation of BPA metabolism was
considered for both the liver and the GI tract. However, in the
simulation of Edginton and Ritter (2009), only maturation of
hepatic metabolism of BPA was considered for the extrapolation
of the adult human model to infants.
MODEL UNCERTAINTY
Professional judgment and interpretation of the literature played
an important role in creating the BPA PBPK models. Gaps in
data and knowledge exist for a quantitative understanding of the
role of the GI tract in the disposition of BPA, e.g., conjugation
of BPA in enterocytes and protein transporters for translocation
of BPA and BPA metabolites, as well as bacterial de-conjugation
of BPA metabolites (enterohepatic recirculation). Furthermore,
no clinical pharmacokinetic studies exist for children or infants,
so the model simulations are simply predictions using the best
available extrapolation tools. The experimental animal kinetic
data sets with d6-BPA help to reduce the uncertainty for the
kinetic behavior of BPA, thus PBPK model development based
on these data represent a solid foundation for age- and species-
extrapolation.
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FIGURE 2 | Model simulated daily area under the serum concentration time curve (AUC) and peak concentration (Cmax ) of d6-BPA at steady state in
rats, monkeys, and humans. Repeated daily oral dosing of 50 µg/kg of d6-BPA was simulated for 5–14 days to ensure that serum d6-BPA concentrations
reached steady state levels.
Our reported sensitivity analyses for the BPA PBPK models
(Fisher et al., 2011; Yang et al., 2013) suggest that both physio-
logical and BPA specific model parameters are sensitive. The most
sensitive model parameters in the monkey were related to the
metabolism of BPA in the liver and oral uptake and metabolism of
BPA in the GI tract. Experimental studies related to these sensitive
model parameters could help refine the model parameter values.
MODEL APPLICATIONS
The human BPA PBPK model performed well in comparison
with experimental data (Völkel et al., 2002), with excellent fit to
the time course of plasma BPA-c concentrations and predicted
plasma BPA levels below the limit of detection (10 nM). One
application of the current human PBPK model for BPA is to
evaluate the expected serum concentrations of unconjugated BPA
in the general adult population and for women of childbearing age
(Teeguarden et al., 2013) using estimated BPA exposures from all
sources of exposure (Lakind and Naiman, 2008). In the paper of
Teeguarden et al. (2013), our model simulations predicted serum
unconjugated BPA concentrations in the range of sub pM to pM
for orally ingested BPA. These predictions were consistent with
the calculated aglycone serum BPA concentrations reported in
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this paper (Teeguarden et al., 2013). For a small subset of mea-
sured aglycone serum BPA concentrations, the model predictions
were much less, questioning the plausibility of these particular
measurements in human serum.
In conclusion, our efforts to unveil quantitatively some of
the complexities in the pharmacokinetics of BPA and its con-
jugates across species provide important information regarding
dose-response toxicity studies with rats, including immature rats,
and the interpretation of biomonitoring data. The character-
ization of BPA-c across species offers a better understanding
of how the conjugates are formed, processed, and excreted.
BPA dosimetry estimated in immature rats after oral dosing
appears to over-predict BPA dosimetry in neonatal monkeys,
suggesting that dose adjustment would be necessary if extrap-
olation of toxicity findings from immature rats to infants and
children.
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